Novartis' soon-to-be-divested Sandoz unit has filed its proposed biosimilar of Amgen's osteoporosis therapy Prolia/Xgeva with the FDA, saying it is "among the first" to fi
Eisai didn't reveal sales of its new Alzheimer's disease therapy Leqembi in its third-quarter update, but said the launch was running "ahead of expectations" since the dru
Kenji Yasukawa is stepping down as chief executive of Japanese pharma group Astellas, to be succeeded by Naoki Okamura – currently chief strategy officer – on 1st April.
The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market
